Neola Medical AB (publ) (NEOLA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's webcast with Unola Medical, where CEO Hanna Sjöström and CFO David Folkesson will present the year-end report for 2024. After the presentation, there will be a Q&A session, so if you have any questions for the company, you can submit them using the form on the right. And with that said, I hand over the word to Johanna. Thank you so much. And hello, everyone. Following this presentation today, we're really excited to summarize 2024 of key strategic process for Neola Medical. And of course, today is also an opportunity to dig into some of the details of our planned clinical study on preterm born infants. My name is Hanna Sjøström and I'm the CEO of Neola Medical since 2019 and with me here today also have our CFO David Folkesson. And today I will start by just introducing the company quickly and also give a flavor of the change that we have seen from 2024 and the key updates. And then I'll also dwell into the details of the Q4 key achievements, but also discuss a bit forward-looking in terms of what we have in front of us for 2025. And of course, David will also cover our financials for 2024. As I will be looking a bit ahead today, I just wanted to make sure that you're also aware that we're now in a phase of greater complexity, especially regarding the regulatory landscape. But we also do see more risk adding to the company as we have moved from the technical phase to the clinical phase of the company where we typically have more unforeseen events. But most importantly, we have taken an important step towards going to the market with our medical device Neola Neonatal Lung Analyzer in 2024. Our medical device is a class two device that for the very first time can monitor the lungs of preterm born infants with an instant detection of lung complication...